Figure 2 | Genetics in Medicine

Figure 2

From: Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings

Figure 2

Percentage of participants rating clinical actions as “very important,” by specialty and finding. Findings include a pathogenic RYR1 variant associated with risk for malignant hyperthermia (“ACMG list”), a pathogenic PALB2 variant associated with risk for breast cancer risk (“Has ClinGen summary”), a pathogenic CHEK2 variant associated with risk for cancer (“No ClinGen summary”), a BRCA1 variant of uncertain significance in a patient with a family history of ovarian cancer (“VUS w family history”), and carrier status for three autosomal recessive conditions. P values summarize tests for nonequivalence comparing genetic specialists and nongenetic specialists (“specialty”) and comparing findings (“finding”), and include a test for interaction between specialty and finding (“interaction”). *p = 0.02733 in analyses with imputed data. †Genetic specialists were not presented this item. ACMG, American College of Medical Genetics and Genomics.

Back to article page